期刊
CANCER BIOLOGY & THERAPY
卷 23, 期 1, 页码 1-13出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/15384047.2022.2132008
关键词
LncRNA DUXAP8; AKT; EZH2; breast cancer; radioresistance
类别
资金
- Wuhan knowledge innovation special basic research project [2022020801010575]
This study found that DUXAP8 plays a critical role in radiation resistance in breast cancer. High expression of DUXAP8 is associated with poor prognosis. DUXAP8 enhances radioresistance of breast cancer cells by modulating the PI3K/AKT/mTOR pathway and interacting with EZH2.
Radiation resistance poses a major clinical challenge in breast cancer (BC) treatment, but little is known about how long noncoding RNA (lncRNA) may regulate this phenomenon. Here, we reported that DUXAP8 was highly expressed in radioresistant BC tissues, and high expression of DUXAP8 was associated with poor prognosis. We found that the overexpression of DUXAP8 promoted radioresistance, while the knockdown of DUXAP8 expression increased radiosensitivity. Further studies revealed that DUXAP8 enhanced the radioresistance of BC cells by activating the PI3K/AKT/mTOR pathway and by repressing the expression of E-cadherin and RHOB through interaction with EZH2. Together, our work demonstrates that the overexpression of DUXAP8 promotes the resistance of BC cells toward radiation through modulating PI3K/AKT/mTOR pathway and EZH2-E-cadherin/RHOB axis. Targeting DUXAP8 may serve as a potential strategy to overcome radioresistance in BC treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据